|
1
|
Jobard E, Dossus L, Baglietto L, Fornili
M, Lécuyer L, Mancini FR, Gunter MJ, Trédan O, Boutron-Ruault MC,
Elena-Herrmann B, et al: Investigation of circulating metabolites
associated with breast cancer risk by untargeted metabolomics: A
case-control study nested within the French E3N cohort. Br J
Cancer. 124:1734–1743. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang Q and Xu R: MetabolitePredict: A de
novo human metabolomics prediction system and its applications in
rheumatoid arthritis. J Biomed Inform. 71:222–228. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Silva CL, Olival A, Perestrelo R, Silva P,
Tomás H and Câmara JS: Untargeted urinary1H NMR-based
metabolomic pattern as a potential platform in breast cancer
detection. Metabolites. 9(269)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Morad HM, Abou-Elzahab MM, Aref S and
El-Sokkary AMA: Diagnostic value of 1H NMR-based
metabolomics in acute lymphoblastic leukemia, acute myeloid
leukemia, and breast cancer. ACS Omega. 7:8128–8140.
2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Patel A: Benign vs malignant tumors. JAMA
Oncol. 6(1488)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Britt KL, Cuzick J and Phillips KA: Key
steps for effective breast cancer prevention. Nat Rev Cancer.
20:417–436. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. 149:778–789. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Anastasiadi Z, Lianos GD, Ignatiadou E,
Harissis HV and Mitsis M: Breast cancer in young women: An
overview. Updates Surg. 69:313–317. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nicolini A, Ferrari P and Duffy MJ:
Prognostic and predictive biomarkers in breast cancer: Past,
present and future. Semin Cancer Biol. 52:56–73. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li J, Guan X, Fan Z, Ching LM, Li Y, Wang
X, Cao WM and Liu DX: Non-invasive biomarkers for early detection
of breast cancer. Cancers (Basel). 12(2767)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Barzaman K, Karami J, Zarei Z,
Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and
Farahmand L: Breast cancer: Biology, biomarkers, and treatments.
Int Immunopharmacol. 84(106535)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Barzaman K, Karami J, Zarei Z,
Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and
Farahmand L: Breast cancer: Biology, biomarkers, and treatments.
Int Immunopharmacol. 84(106535)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sharma GN, Dave R, Sanadya J, Sharma P and
Sharma KK: Various types and management of breast cancer: An
overview. J Adv Pharm Technol Res. 1:109–126. 2010.PubMed/NCBI
|
|
15
|
Akram M, Iqbal M, Daniyal M and Khan AU:
Awareness and current knowledge of breast cancer. Biol Res.
50(33)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z,
Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer
development and progression: Risk factors, cancer stem cells,
signaling pathways, genomics, and molecular pathogenesis. Genes
Dis. 5:77–106. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Thirumurugan D, Cholarajan A, Raja SSS and
Vijayakumar R: An introductory chapter: Secondary metabolites. In:
Vijayakumar R, Raja SSS (edis). Secondary Metabolites-Sources and
Applications. Crotia: InTech-Open Science, pp138, 2018.
|
|
18
|
Chen H and Wang L: Sugar strategies for
biomass biochemical conversion. Technologies for Biochemical
Conversion of Biomass. Metallurgical Industry Press, pp137-164,
2017.
|
|
19
|
Abdel-Aziz SM, Abo Elsoud MM and Anise
AAH: Microbial biosynthesis: A repertory of vital natural products.
Food Biosynthesis. Elsevier Inc., 25-54, 2017.
|
|
20
|
Tiwari R and Rana CS: Plant secondary
metabolites: A review. Int J Eng Res Gen Sci. 3:661–670. 2015.
|
|
21
|
Chandran H, Meena M, Barupal T and Sharma
K: Plant tissue culture as a perpetual source for production of
industrially important bioactive compounds. Biotechnol Rep (Amst).
26(e00450)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Abdullah MA, Bahamid AAA, Alshajrawi OMS,
Nazir MS and Tahir Z: Integrated biomaterials engineering of oil
palm fibres and microalgae for bioenergy, environmental
remediation, and conversion into value-added-products. IOP Conf Ser
Earth Environ Sci. 448(012091)2020.
|
|
23
|
Jones DP, Park Y and Ziegler TR:
Nutritional metabolomics: Progress in addressing complexity in diet
and health. Annu Rev Nutr. 32:183–202. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hanna VS and Hafez EAA: Synopsis of
arachidonic acid metabolism: A review. J Adv Res. 11:23–32.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pezzuto F, Buonaguro L, Buonaguro FM and
Tornesello ML: The role of circulating free DNA and MicroRNA in
non-invasive diagnosis of HBV- and HCV-related hepatocellular
carcinoma. Int J Mol Sci. 19(1007)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lu T and Li J: Clinical applications of
urinary cell-free DNA in cancer: Current insights and promising
future. Am J Cancer Res. 7:2318–2332. 2017.PubMed/NCBI
|
|
27
|
Nam H, Chung BC, Kim Y, Lee KY and Lee D:
Combining tissue transcriptomics and urine metabolomics for breast
cancer biomarker identification. Bioinformatics. 25:3151–3157.
2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Henneges C, Bullinger D, Fux R, Friese N,
Seeger H, Neubauer H, Laufer S, Gleiter CH, Schwab M, Zell A and
Kammerer B: Prediction of breast cancer by profiling of urinary RNA
metabolites using Support Vector Machine-based feature selection.
BMC Cancer. 9(104)2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dinges SS, Hohm A, Vandergrift LA, Nowak
J, Habbel P, Kaltashov IA and Cheng LL: Cancer metabolomic markers
in urine: Evidence, techniques and recommendations. Nat Rev Urol.
16:339–362. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Frickenschmidt A, Frohlich H, Bullinger D,
Zell A, Laufer S, Gleiter CH, Liebich H and Kammerer B:
Metabonomics in cancer diagnosis: Mass spectrometry-based profiling
of urinary nucleosides from breast cancer patients. Biomarkers.
13:435–449. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen Y, Zhang R, Song Y, He J, Sun J, Bai
J, An Z, Dong L, Zhan Q and Abliz Z: RRLC-MS/MS-based metabonomics
combined with in-depth analysis of metabolic correlation network:
Finding potential biomarkers for breast cancer. Analyst.
134:2003–2011. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cho SH, Jung BH, Lee SH, Lee WY, Kong G
and Chung BC: Direct determination of nucleosides in the urine of
patients with breast cancer using column-switching liquid
chromatography-tandem mass spectrometry. Biomed Chromatogr.
20:1229–1236. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lécuyer L, Victor Bala A, Deschasaux M,
Bouchemal N, Nawfal Triba M, Vasson MP, Rossary A, Demidem A, Galan
P, Hercberg S, et al: NMR metabolomic signatures reveal predictive
plasma metabolites associated with long-term risk of developing
breast cancer. Int J Epidemiol. 47:484–494. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lecuyer L, Dalle C, Lyan B, Demidem A,
Rossary A, Vasson MP, Petera M, Lagree M, Ferreira T, Centeno D, et
al: Plasma metabolomic signatures associated with long-term breast
cancer risk in the SU.VI.MAX prospective cohort. Cancer Epidemiol
Biomarkers Prev. 28:1300–1307. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
An R, Yu H, Wang Y, Lu J, Gao Y, Xie X and
Zhang J: Integrative analysis of plasma metabolomics and proteomics
reveals the metabolic landscape of breast cancer. Cancer Metab.
10(13)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gasparri ML, Casorelli A, Bardhi E,
Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller
MD, Ferretti E and Benedetti Panici P: Beyond circulating microRNA
biomarkers: Urinary microRNAs in ovarian and breast cancer. Tumour
Biol. 39(1010428317695525)2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ilyas MN, Ab A, Al-Hatamleh MAI,
Al-Shajrawi OM, Ariff TM and Simbak N: Rising trends of obesity in
Malaysia; role of inflammation and inflammatory markers in obesity
related insulin resistance: A nuclear factor kappa B (Nfkb)
perspective. Exp Clin Endocrinol Diabetes. 109:S135–S148. 2017.
|
|
38
|
Rudnicka E, Suchta K, Grymowicz M,
Calik-Ksepka A, Smolarczyk K, Duszewska AM, Smolarczyk R and
Meczekalski B: Chronic low grade inflammation in pathogenesis of
PCOS. Int J Mol Sci. 22(3789)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Slupsky CM, Steed H, Wells TH, Dabbs K,
Schepansky A, Capstick V, Faught W and Sawyer MB: Urine metabolite
analysis offers potential early diagnosis of ovarian and breast
cancers. Clin Cancer Res. 16:5835–5841. 2010.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Bax C, Lotesoriere BJ, Sironi S and
Capelli L: Review and comparison of cancer biomarker trends in
urine as a basis for new diagnostic pathways. Cancers (Basel).
11(1244)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Cala M, Aldana J, Sánchez J, Guio J and
Meesters RJW: Urinary metabolite and lipid alterations in Colombian
Hispanic women with breast cancer: A pilot study. J Pharm Biomed
Anal. 152:234–241. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Pasikanti KK, Esuvaranathan K, Hong Y, Ho
PC, Mahendran R, Raman Nee Mani L, Chiong E and Chan EC: Urinary
metabotyping of bladder cancer using two-dimensional gas
chromatography time-of-flight mass spectrometry. J Proteome Res.
12:3865–3873. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Silva C, Perestrelo R, Silva P, Tomás H
and Câmara JS: Breast cancer metabolomics: From analytical
platforms to multivariate data analysis. A review. Metabolites.
9(102)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Putluri N, Shojaie A, Vasu VT, Vareed SK,
Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C,
et al: Metabolomic profiling reveals potential markers and
bioprocesses altered in bladder cancer progression. Cancer Res.
71:7376–7386. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yu L, Jiang C, Huang S, Gong X, Wang S and
Shen P: Analysis of urinary metabolites for breast cancer patients
receiving chemotherapy by CE-MS coupled with on-line concentration.
Clin Biochem. 46:1065–1073. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Woo HM, Kim KM, Choi MH, Jung BH, Lee J,
Kong G, Nam SJ, Kim S, Bai SW and Chung BC: Mass spectrometry based
metabolomic approaches in urinary biomarker study of women's
cancers. Clin Chim Acta. 400:63–69. 2009.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Men Y, Li L, Zhang F, Kong X, Zhang W, Hao
C and Wang G: Evaluation of heavy metals and metabolites in the
urine of patients with breast cancer. Oncol Lett. 19:1331–1337.
2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Asiago VM, Alvarado LZ, Shanaiah N, Gowda
GAN, Owusu-Sarfo K, Ballas RA and Raftery D: Early detection of
recurrent breast cancer using metabolite profiling. Cancer Res.
70:8309–8318. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Oakman C, Tenori L, Claudino WM, Cappadona
S, Nepi S, Battaglia A, Bernini P, Zafarana E, Saccenti E, Fornier
M, et al: Identification of a serum-detectable metabolomic
fingerprint potentially correlated with the presence of
micrometastatic disease in early breast cancer patients at varying
risks of disease relapse by traditional prognostic methods. Ann
Oncol. 22:1295–1301. 2011.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Tenori L, Oakman C, Claudino WM, Bernini
P, Cappadona S, Nepi S, Biganzoli L, Arbushites MC, Luchinat C,
Bertini I and Di Leo A: Exploration of serum metabolomic profiles
and outcomes in women with metastatic breast cancer: A pilot study.
Mol Oncol. 6:437–444. 2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wei S, Liu L, Zhang J, Bowers J, Gowda
GAN, Seeger H, Fehm T, Neubauer HJ, Vogel U, Clare SE and Raftery
D: Metabolomics approach for predicting response to neoadjuvant
chemotherapy for breast cancer. Mol Oncol. 7:297–307.
2013.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Jobard E, Pontoizeau C, Blaise BJ,
Bachelot T, Elena-Herrmann B and Trédan O: A serum nuclear magnetic
resonance-based metabolomic signature of advanced metastatic human
breast cancer. Cancer Lett. 343:33–41. 2014.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Tenori L, Oakman C, Morris PG, Gralka E,
Turner N, Cappadona S, Fornier M, Hudis C, Norton L, Luchinat C and
Di Leo A: Serum metabolomic profiles evaluated after surgery may
identify patients with oestrogen receptor negative early breast
cancer at increased risk of disease recurrence. Results from a
retrospective study. Mol Oncol. 9:128–139. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Kim Y, Koo I, Jung BH, Chung BC and Lee D:
Multivariate classification of urine metabolome profiles for breast
cancer diagnosis. BMC Bioinformatics. 11 (Suppl
2)(S4)2010.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Bathen TF, Geurts B, Sitter B, Fjøsne HE,
Lundgren S, Buydens LM, Gribbestad IS, Postma G and Giskeødegård
GF: Feasibility of MR metabolomics for immediate analysis of
resection margins during breast cancer surgery. PLoS One.
8(e61578)2013.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Borgan E, Sitter B, Lingjærde OC, Johnsen
H, Lundgren S, Bathen TF, Sørlie T, Børresen-Dale AL and Gribbestad
IS: Merging transcriptomics and metabolomics-advances in breast
cancer profiling. BMC Cancer. 10(628)2010.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Debik J, Euceda LR, Lundgren S, Gythfeldt
HDVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF and Giskeødegård
GF: Assessing treatment response and prognosis by serum and tissue
metabolomics in breast cancer patients. J Proteome Res.
18:3649–3660. 2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Haukaas TH, Euceda LR, Giskeødegård GF,
Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC,
Schlichting E, Garred Ø, et al: Metabolic clusters of breast cancer
in relation to gene- and protein expression subtypes. Cancer Metab.
4(12)2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Chae EY, Shin HJ, Kim S, Baek HM, Yoon D,
Kim S, Shim YE, Kim HH, Cha JH, Choi WJ, et al: The role of
high-resolution magic angle spinning 1H nuclear magnetic resonance
spectroscopy for predicting the invasive component in patients with
ductal carcinoma in situ diagnosed on preoperative biopsy. PLoS
One. 11(e0161038)2016.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Euceda LR, Haukaas TH, Giskeødegård GF,
Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E,
Garred Y, Garred G, et al: Evaluation of metabolomic changes during
neoadjuvant chemotherapy combined with bevacizumab in breast cancer
using MR spectroscopy. Metabolomics. 13(37)2017.
|
|
61
|
Cala MP, Aldana J, Medina J, Sánchez J,
Guio J, Wist J and Meesters RJW: Multiplatform plasma metabolic and
lipid fingerprinting of breast cancer: A pilot control-case study
in Colombian Hispanic women. PLoS One. 13(e0190958)2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Lécuyer L, Victor Bala A, Deschasaux M,
Bouchemal N, Nawfal Triba M, Vasson MP, Rossary A, Demidem A, Galan
P, Hercberg S, et al: NMR metabolomic signatures reveal predictive
plasma metabolites associated with long-term risk of developing
breast cancer. Int J Epidemiol. 47:484–494. 2018.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Suman S, Sharma RK, Kumar V, Sinha N and
Shukla Y: Metabolic fingerprinting in breast cancer stages through
1H NMR spectroscopy-based metabolomic analysis of
plasma. J Pharm Biomed Anal. 160:38–45. 2018.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Louis E, Bervoets L, Reekmans G, De Jonge
E, Mesotten L, Thomeer M and Adriaensens P: Phenotyping human blood
plasma by 1H-NMR: A robust protocol based on metabolite
spiking and its evaluation in breast cancer. Metabolomics.
11:225–236. 2015.
|
|
65
|
Vignoli A, Muraro E, Miolo G, Tenori L,
Turano P, Di Gregorio E, Steffan A, Luchinat C and Corona G: Effect
of estrogen receptor status on circulatory immune and metabolomics
profiles of HER2-positive breast cancer patients enrolled for
neoadjuvant targeted chemotherapy. Cancers (Basel).
12(314)2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
McCartney A, Vignoli A, Tenori L, Fornier
M, Rossi L, Risi E, Luchinat C, Biganzoli L and Di Leo A:
Metabolomic analysis of serum may refine 21-gene expression assay
risk recurrence stratification. NPJ Breast Cancer.
5(26)2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Jiang L, Lee SC and Ng TC:
Pharmacometabonomics analysis reveals serum formate and acetate
potentially associated with varying response to
gemcitabine-carboplatin chemotherapy in metastatic breast cancer
patients. J Proteome Res. 17:1248–1257. 2018.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Wojtowicz W, Wróbel A, Pyziak K, Tarkowski
R, Balcerzak A, Bębenek M and Młynarz P: Evaluation of MDA-MB-468
cell culture media analysis in predicting triple-negative breast
cancer patient sera metabolic profiles. Metabolites.
10(173)2020.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Men Y, Li L, Zhang F, Kong X, Zhang W, Hao
C, et al: Evaluation of heavy metals and metabolites in the urine
of patients with breast cancer. Oncol Lett. 19:1331–1337.
2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Li N, Deng Y, Zhou L, Tian T, Yang S, Wu
Y, Zheng Y, Zhai Z, Hao Q, Song D, et al: Global burden of breast
cancer and attributable risk factors in 195 countries and
territories, from 1990 to 2017: Results from the Global Burden of
Disease Study 2017. J Hematol Oncol. 12(140)2019.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Slupsky CM, Steed H, Wells TH, Dabbs K,
Schepansky A, Capstick V, Faught W and Sawyer MB: Urine metabolite
analysis offers potential early diagnosis of ovarian and breast
cancers. Clin Cancer Res. 16:5835–5841. 2010.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Lau AN and Vander Heiden MG: Metabolism in
the tumor microenvironment. Annu Rev Cancer Biol. 4:17–40.
2020.
|
|
74
|
Phan LM, Yeung SCJ and Lee MH: Cancer
metabolic reprogramming: Importance, main features, and potentials
for precise targeted anti-cancer therapies. Cancer Biol Med.
11:1–19. 2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Sullivan LB, Gui DY and Van Der Heiden MG:
Altered metabolite levels in cancer: Implications for tumour
biology and cancer therapy. Nat Rev Cancer. 16:680–693.
2016.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Gu I, Gregory E, Atwood C, Lee SO and Song
YH: Exploring the role of metabolites in cancer and the associated
nerve crosstalk. Nutrients. 14(1722)2022.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Potter M, Newport E and Morten KJ: The
Warburg effect: 80 Years on. Biochem Soc Trans. 44:1499–1505.
2016.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Nalbantoglu S and Karadag A: Metabolomics
bridging proteomics along metabolites/oncometabolites and protein
modifications: Paving the way toward integrative multiomics. J
Pharm Biomed Anal. 199(114031)2021.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Kinnaird A, Zhao S, Wellen KE and
Michelakis ED: Metabolic control of epigenetics in cancer. Nat Rev
Cancer. 16:694–707. 2016.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Al-Shajrawi OM, Basit E and Baig AA: HIF1
(rs11549465) and NFKB1 (rs28362491) variants association with
obesity in Malaysia. Meta Gene. 25(100753)2020.
|
|
81
|
Choi YK and Park KG: Targeting glutamine
metabolism for cancer treatment. Biomol Ther (Seoul). 26:19–28.
2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Butler M, van der Meer LT and van Leeuwen
FN: Amino acid depletion therapies: Starving cancer cells to death.
Trends Endocrinol Metab. 32:367–381. 2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Wang ZH, Peng WB, Zhang P, Yang XP and
Zhou Q: Lactate in the tumour microenvironment: From immune
modulation to therapy. EBioMedicine. 73(103627)2021.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Doldo E, Costanza G, Agostinelli S,
Tarquini C, Ferlosio A, Arcuri G, Passeri D, Scioli MG and Orlandi
A: Vitamin A, cancer treatment and prevention: The new role of
cellular retinol binding proteins. Biomed Res Int.
2015(624627)2015.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Zeng LH, Wang QM, Feng LY, Ke YD, Xu QZ,
Wei AY, Zhang C and Ying RB: High-dose vitamin C suppresses the
invasion and metastasis of breast cancer cells via inhibiting
epithelial-mesenchymal transition. Onco Targets Ther. 12:7405–7413.
2019.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Sailo BL, Banik K, Padmavathi G, Javadi M,
Bordoloi D and Kunnumakkara AB: Tocotrienols: The promising
analogues of vitamin E for cancer therapeutics. Pharmacol Res.
130:259–272. 2018.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Miyazawa S, Moriya S, Kokuba H, Hino H,
Takano N and Miyazawa K: Vitamin K2 induces
non-apoptotic cell death along with autophagosome formation in
breast cancer cell lines. Breast Cancer. 27:225–235.
2020.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Qiu F, Chen YR, Liu X, Chu CY, Shen LJ, Xu
J, Gaur S, Forman HJ, Zhang H, Zheng S, et al: Arginine starvation
impairs mitochondrial respiratory function in ASS1-deficient breast
cancer cells. Sci Signal. 7(ra31)2014.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Cheng CT, Qi Y, Wang YC, Chi KK, Chung Y,
Ouyang C, Chen YR, Oh ME, Sheng X, Tang Y, et al: Arginine
starvation kills tumor cells through aspartate exhaustion and
mitochondrial dysfunction. Commun Biol. 1(178)2018.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Ji JX, Cochrane DR, Tessier-Cloutier B,
Chen SY, Ho G, Pathak KV, Alcazar IN, Farnell D, Leung S, Cheng A,
et al: Arginine depletion therapy with ADI-PEG20 limits tumor
growth in argininosuccinate synthase-deficient ovarian cancer,
including small-cell carcinoma of the ovary, hypercalcemic type.
Clin Cancer Res. 26:4402–4413. 2020.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Krall AS, Xu S, Graeber TG, Braas D and
Christofk HR: Asparagine promotes cancer cell proliferation through
use as an amino acid exchange factor. Nat Commun.
7(11457)2016.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Hoang G, Udupa S and Le A: Application of
metabolomics technologies toward cancer prognosis and therapy. Int
Rev Cell Mol Biol. 347:191–223. 2019.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Elgogary A, Xu Q, Poore B, Alt J,
Zimmermann SC, Zhao L, Fu J, Chen B, Xia S, Liu Y, et al:
Combination therapy with BPTES nanoparticles and metformin targets
the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad
Sci USA. 113:E5328–E5336. 2016.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Lane AN, Fan TWM and Higashi RM:
Isotopomer-based metabolomic analysis by NMR and mass spectrometry.
Methods Cell Biol. 84:541–588. 2008.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Le A, Lane AN, Hamaker M, Bose S, Gouw A,
Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al:
Glucose-independent glutamine metabolism via TCA cycling for
proliferation and survival in B cells. Cell Metab. 15:110–121.
2012.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Beger R: A review of applications of
metabolomics in cancer. Metabolites. 3:552–574. 2013.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Zhang A, Sun H, Wang P, Han Y and Wang X:
Modern analytical techniques in metabolomics analysis. Analyst.
137:293–300. 2012.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Lyon DE, Starkweather A, Yao Y, Garrett T,
Kelly DL, Menzies V, Dereziński P, Datta S, Kumar S and
Jackson-Cook C: Pilot study of metabolomics and psychoneurological
symptoms in women with early stage breast cancer. Biol Res Nurs.
20:227–236. 2018.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Silva CL, Perestrelo R, Silva P, Tomás H
and Câmara JS: Volatile metabolomic signature of human breast
cancer cell lines. Sci Rep. 7(43969)2017.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Cífková E, Lísa M, Hrstka R, Vrána D,
Gatěk J, Melichar B and Holčapek M: Correlation of lipidomic
composition of cell lines and tissues of breast cancer patients
using hydrophilic interaction liquid chromatography/electrospray
ionization mass spectrometry and multivariate data analysis. Rapid
Commun Mass Spectrom. 31:253–263. 2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Cavaco C, Pereira JAM, Taunk K, Taware R,
Rapole S, Nagarajaram H and Câmara JS: Screening of salivary
volatiles for putative breast cancer discrimination: An exploratory
study involving geographically distant populations. Anal Bioanal
Chem. 410:445–468. 2018.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Porto-Figueira P, Pereira JAM and Câmara
JS: Exploring the potential of needle trap microextraction combined
with chromatographic and statistical data to discriminate different
types of cancer based on urinary volatomic biosignature. Anal Chim
Acta. 1023:53–63. 2018.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Budczies J, Brockmöller SF, Müller BM,
Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, Griffin JL,
Orešič M, Dietel M, Denkert C and Fiehn O: Comparative metabolomics
of estrogen receptor positive and estrogen receptor negative breast
cancer: Alterations in glutamine and beta-alanine metabolism. J
Proteomics. 94:279–288. 2013.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Dougan MM, Li Y, Chu LW, Haile RW,
Whittemore AS, Han SS, Moore SC, Sampson JN, Andrulis IL, John EM
and Hsing AW: Metabolomic profiles in breast cancer: A pilot
case-control study in the breast cancer family registry. BMC
Cancer. 18(532)2018.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Sas KM, Karnovsky A, Michailidis G and
Pennathur S: Metabolomics and diabetes: Analytical and
computational approaches. Diabetes. 64:718–732. 2015.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Ahad T and Nissar J: Fingerprinting in
determining the adultration of food. J Pharmacogn Phytochem.
6:1543–1553. 2017.
|
|
107
|
Claudino WM, Goncalves PH, di Leo A,
Philip PA and Sarkar FH: Metabolomics in cancer: A bench-to-bedside
intersection. Crit Rev Oncol Hematol. 84:1–7. 2012.PubMed/NCBI View Article : Google Scholar
|
|
108
|
De Castro F, Benedetti M, Del Coco L and
Fanizzi FP: NMR-based metabolomics in metal-based drug research.
Molecules. 24(2240)2019.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Cacciola F, Farnetti S, Dugo P, Marriott
PJ and Mondello L: Comprehensive two-dimensional liquid
chromatography for polyphenol analysis in foodstuffs. J Sep Sci.
40:7–24. 2017.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Emwas AHM: The strengths and weaknesses of
NMR spectroscopy and mass spectrometry with particular focus on
metabolomics research. Methods Mol Biol. 1277:161–193.
2015.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Beltran A, Suarez M, Rodríguez MA, Vinaixa
M, Samino S, Arola L, Correig X and Yanes O: Assessment of
compatibility between extraction methods for NMR- and LC/MS-based
metabolomics. Anal Chem. 84:5838–5844. 2012.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Emwas AH, Roy R, McKay RT, Tenori L,
Saccenti E, Gowda GAN, Raftery D, Alahmari F, Jaremko L, Jaremko M
and Wishart DS: Nmr spectroscopy for metabolomics research.
Metabolites. 9(123)2019.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Dunn WB, Broadhurst DI, Atherton HJ,
Goodacre R and Griffin JL: Systems level studies of mammalian
metabolomes: The roles of mass spectrometry and nuclear magnetic
resonance spectroscopy. Chem Soc Rev. 40:387–426. 2011.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S
and Zhang A: Small molecule metabolites: Discovery of biomarkers
and therapeutic targets. Signal Transduct Target Ther.
8(132)2023.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Burke HB: Predicting clinical outcomes
using molecular biomarkers. Biomark Cancer. 8:89–99.
2016.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Carlomagno N, Incollingo P, Tammaro V,
Peluso G, Rupealta N, Chiacchio G, Sandoval Sotelo ML, Minieri G,
Pisani A, Riccio E, et al: Diagnostic, predictive, prognostic, and
therapeutic molecular biomarkers in third millennium: A
breakthrough in gastric cancer. Biomed Res Int.
2017(7869802)2017.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Mayeux R: Biomarkers: Potential uses and
limitations. NeuroRx. 1:182–188. 2004.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Duffy MJ, Harbeck N, Nap M, Molina R,
Nicolini A, Senkus E and Cardoso F: Clinical use of biomarkers in
breast cancer: Updated guidelines from the European Group on Tumor
Markers (EGTM). Eur J Cancer. 75:284–298. 2017.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Brennan M and Lim B: The actual role of
receptors as cancer markers, biochemical and clinical aspects:
Receptors in breast cancer. Adv Exp Med Biol. 867:327–337.
2015.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Li Z, Wei H, Li S, Wu P and Mao X: The
role of progesterone receptors in breast cancer. Drug Des Devel
Ther. 16:305–314. 2022.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Brisken C, Hess K and Jeitziner R:
Progesterone and overlooked endocrine pathways in breast cancer
pathogenesis. Endocrinology. 156:3442–3450. 2015.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Trabert B, Sherman ME, Kannan N and
Stanczyk FZ: Progesterone and breast cancer. Endocr Rev.
41:320–344. 2020.PubMed/NCBI View Article : Google Scholar
|
